172 related articles for article (PubMed ID: 36088452)
1. PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data.
Wu S; Le Prieult F; Phipps CJ; Mezler M; Shah DK
J Pharmacokinet Pharmacodyn; 2022 Dec; 49(6):579-592. PubMed ID: 36088452
[TBL] [Abstract][Full Text] [Related]
2. A translational platform PBPK model for antibody disposition in the brain.
Chang HY; Wu S; Meno-Tetang G; Shah DK
J Pharmacokinet Pharmacodyn; 2019 Aug; 46(4):319-338. PubMed ID: 31115858
[TBL] [Abstract][Full Text] [Related]
3. Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system.
Chang HY; Wu S; Chowdhury EA; Shah DK
J Pharmacokinet Pharmacodyn; 2022 Jun; 49(3):337-362. PubMed ID: 35092540
[TBL] [Abstract][Full Text] [Related]
4. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
Shah DK; Betts AM
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
[TBL] [Abstract][Full Text] [Related]
5. Investigation of Antibody Pharmacokinetics in the Brain Following Intra-CNS Administration and Development of PBPK Model to Characterize the Data.
Wu S; Chang HY; Chowdhury EA; Huang HW; Shah DK
AAPS J; 2024 Mar; 26(2):29. PubMed ID: 38443635
[TBL] [Abstract][Full Text] [Related]
6. Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1.
Khot A; Tibbitts J; Rock D; Shah DK
AAPS J; 2017 Nov; 19(6):1715-1734. PubMed ID: 28808917
[TBL] [Abstract][Full Text] [Related]
7. Clinical validation of translational antibody PBPK model using tissue distribution data generated with
Liu S; Li Z; Huisman M; Shah DK
J Pharmacokinet Pharmacodyn; 2023 Oct; 50(5):377-394. PubMed ID: 37382712
[TBL] [Abstract][Full Text] [Related]
8. Whole-Body Disposition and Physiologically Based Pharmacokinetic Modeling of Adeno-Associated Viruses and the Transgene Product.
Liu S; Chowdhury EA; Xu V; Jerez A; Mahmood L; Ly BQ; Le HK; Nguyen A; Rajwade A; Meno-Tetang G; Shah DK
J Pharm Sci; 2024 Jan; 113(1):141-157. PubMed ID: 37805073
[TBL] [Abstract][Full Text] [Related]
9. Expansion of platform physiologically-based pharmacokinetic model for monoclonal antibodies towards different preclinical species: cats, sheep, and dogs.
Huang HW; Wu S; Chowdhury EA; Shah DK
J Pharmacokinet Pharmacodyn; 2023 Nov; ():. PubMed ID: 37947924
[TBL] [Abstract][Full Text] [Related]
10. Two-pore physiologically based pharmacokinetic model with de novo derived parameters for predicting plasma PK of different size protein therapeutics.
Li Z; Shah DK
J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):305-318. PubMed ID: 31028591
[TBL] [Abstract][Full Text] [Related]
11. Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection.
Pasquiers B; Benamara S; Felices M; Nguyen L; Declèves X
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361546
[TBL] [Abstract][Full Text] [Related]
12. Brain pharmacokinetics of anti-transferrin receptor antibody affinity variants in rats determined using microdialysis.
Chang HY; Wu S; Li Y; Zhang W; Burrell M; Webster CI; Shah DK
MAbs; 2021; 13(1):1874121. PubMed ID: 33499723
[TBL] [Abstract][Full Text] [Related]
13. Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice.
Chang HP; Li Z; Shah DK
Pharm Res; 2022 Jan; 39(1):1-24. PubMed ID: 35044590
[TBL] [Abstract][Full Text] [Related]
14. Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition.
Bordeau BM; Polli JR; Schweser F; Grimm HP; Richter WF; Balthasar JP
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054865
[TBL] [Abstract][Full Text] [Related]
15. Development of a physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies in rabbits.
Bussing D; K Shah D
J Pharmacokinet Pharmacodyn; 2020 Dec; 47(6):597-612. PubMed ID: 32876799
[TBL] [Abstract][Full Text] [Related]
16. Using the LeiCNS-PK3.0 Physiologically-Based Pharmacokinetic Model to Predict Brain Extracellular Fluid Pharmacokinetics in Mice.
Saleh MAA; Gülave B; Campagne O; Stewart CF; Elassaiss-Schaap J; de Lange ECM
Pharm Res; 2023 Nov; 40(11):2555-2566. PubMed ID: 37442882
[TBL] [Abstract][Full Text] [Related]
17. Two-pore physiologically based pharmacokinetic model validation using whole-body biodistribution of trastuzumab and different-size fragments in mice.
Li Z; Li Y; Chang HP; Yu X; Shah DK
J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):743-762. PubMed ID: 34146191
[TBL] [Abstract][Full Text] [Related]
18. Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling.
Hu S; D'Argenio DZ
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):385-409. PubMed ID: 32500362
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and Determination of Tumor Interstitial Distribution of a Therapeutic Monoclonal Antibody Using Large-Pore Microdialysis.
Khaowroongrueng V; Jadhav SB; Syed M; Akbar M; Gertz M; Otteneder MB; Fueth M; Derendorf H
J Pharm Sci; 2021 Aug; 110(8):3061-3068. PubMed ID: 33819461
[TBL] [Abstract][Full Text] [Related]
20. Assessment and Confirmation of Species Difference in Nonlinear Pharmacokinetics of Atipamezole with Physiologically Based Pharmacokinetic Modeling.
Li Z; Gao Y; Yang C; Xiang Y; Zhang W; Zhang T; Su R; Lu C; Zhuang X
Drug Metab Dispos; 2020 Jan; 48(1):41-51. PubMed ID: 31699808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
